Dossier assessment
Abrocitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Abrocitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Abrocitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Moderate to severe atopic dermatitis in adults who are candidates for systemic therapy
Indication of considerable added benefit
Additional information
Federal Joint Committee (G-BA)
07-07-2022 A G-BA decision was published.
Project details
- Project no.
- A22-06
- Commission
- Commission awarded on 17.01.2022 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Skin and hair
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Addendum
Abrocitinib (atopic dermatitis) - Addendum to Commission A22-06
Status: Commission completed
-
Dossier assessment
Abrocitinib (atopic dermatitis, adolescents 12 years and older) – Benefit assessment according to § 35a Social Code Book V
Status: Commission completed